# JYP0015

Source: https://onco.cc/drugs/jyp0015/  
OnCo record `jyp0015` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JYP0015 is an experimental small-molecule drug from Guangzhou JOYO Pharma in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, aimed at KRAS.

## Summary

JYP0015 is a small-molecule drug developed by Guangzhou JOYO Pharma. Its target is KRAS (the sponsor names KRAS, NRAS, HRAS (pan-RAS)). The sponsor states: An orally bioavailable pan-RAS inhibitor designed to selectively target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS and HRAS isoforms, including mutations at codons 12, 13, 61, 117 and 146. ClinicalTrials.gov describes the intervention as: JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer. The largest, NCT06895031, plans to enrol 210 participants with primary completion was scheduled for 2026-03-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule (structure undisclosed or not yet in PubChem)
- Mechanism: An orally bioavailable pan-RAS inhibitor designed to selectively target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS and HRAS isoforms, including mutations at codons 12, 13, 61, 117 and 146.

## Sources

- ClinicalTrials.gov: trials of JYP0015: https://clinicaltrials.gov/search?intr=JYP0015

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [HRAS](https://onco.cc/targets/hras/), [KRAS](https://onco.cc/targets/kras/), [NRAS](https://onco.cc/targets/nras/)
- trials: [Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS](https://onco.cc/trials/nct06895031/)

---
JSON: https://onco.cc/api/v1/entities/jyp0015.json